Zhong Ji Longevity Science Group Ltd

Zhong Ji Longevity Science Group Ltd has a basic and diluted share count of 636,654,300 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company reported a last actual earnings per share (EPS) of -571.00 HKD and revenue of 734,038,000 HKD, indicating a loss-making position and a relatively modest revenue base. These figures suggest that the company is underperforming in terms of profitability and may be struggling to generate returns that meet industry benchmarks.

There is no detailed information available on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. Without this data, it is difficult to determine the extent to which the company is exposed to specific markets or customer bases.

The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of a clear growth narrative and the current loss-making position raise concerns about the company's ability to sustain operations and deliver value to shareholders.

The company's risk profile is characterized by low dilution potential and an inability to assess liquidity risk. The lack of balance-sheet inputs and going-concern language in source documents suggests that the company may be facing operational or financial challenges that are not fully disclosed.

Recent events and filings do not provide additional insights into the company's operations or strategic direction. The absence of detailed disclosures in 10-K Risk Factors or recent transcripts limits the ability to assess the company's exposure to external risks or its response to market conditions.

Revenue surged 155.7% year-over-year to HKD 166.2 million in FY2008, demonstrating significant top-line expansion momentum.

The company achieved a robust 39.6% revenue CAGR over the three-year period ending in fiscal year 2008.

Total assets grew steadily with a 0.5% CAGR, reaching HKD 525.6 million by the end of fiscal year 2008.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

Gross profit fell significantly from HKD 83.8 million in FY2006 to HKD 57.4 million in FY2008 despite revenue growth.

Revenue HK$166.2M, +155,7% YoY; Operating income −568,2% YoY.

• ▍Revenue HK$166.2M, +155,7% YoY
• ▍Operating income −568,2% YoY
• ▍Net income −1 601,3% YoY
• ▍Free cash flow −390,7% YoY
• ▍Net margin -20.9%

Revenue HK$65.0M, −27,5% YoY; Operating income −40,5% YoY.

• ▍Revenue HK$65.0M, −27,5% YoY
• ▍Operating income −40,5% YoY
• ▍Net income +355,9% YoY
• ▍Free cash flow +154,1% YoY
• ▍Net margin 3.6%

Revenue HK$89.7M, +46,7% YoY; Operating income +68,4% YoY.

• ▍Revenue HK$89.7M, +46,7% YoY
• ▍Operating income +68,4% YoY
• ▍Net income −114,9% YoY
• ▍Free cash flow −60,0% YoY
• ▍Net margin -1.0%

Revenue HK$61.1M; Operating income HK$6.8M.

• ▍Revenue HK$61.1M
• ▍Operating income HK$6.8M
• ▍Net margin 9.9%